Press-release for stocks for biohaven pharmaceutical holding company ltd.

Prices are updated after-hours

trial entities : Biohaven pharmaceutical holding company ltd.

save search

Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
Published: 2022-09-29 (Crawled : 13:20) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -71.13% | O: -0.19% H: 0.12% C: -0.07%
als trial update sclerosis platform phase 2

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
Published: 2022-07-07 (Crawled : 12:00) - prnewswire.com
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -69.88% | O: -0.11% H: 0.14% C: -0.17%
trial phase 3

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Published: 2022-07-06 (Crawled : 20:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -69.96% | O: -0.01% H: 0.26% C: -0.26%
vt1021 trial

Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
Published: 2022-06-09 (Crawled : 13:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -69.76% | O: -0.08% H: 0.25% C: -0.26%
nurtec label trial migraine phase 3

Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -68.97% | O: 0.25% H: 1.91% C: 0.92%
trial phase 3

Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
Published: 2022-02-22 (Crawled : 13:00) - prnewswire.com
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -68.58% | O: -1.15% H: 1.44% C: -2.83%
nurtec phase 2 phase 2/3 trial enroll

Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
PFE A | $25.42 -1.05% -0.04% 44M

Health Technology

| -49.94% | O: -1.89% H: 1.36% C: -0.04%
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -67.47% | O: 0.27% H: 2.86% C: 1.95%
treatment trial migraine china topline results positive results topline

Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Published: 2022-01-18 (Crawled : 22:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -64.1% | O: -1.78% H: 0.59% C: -1.67%
phase 2 research trial platform glioblastoma

Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application
Published: 2021-12-06 (Crawled : 13:30) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -59.73% | O: -5.67% H: 0.0% C: 0.0%
new drug application drug trial migraine topline results positive results topline pain relief submission

Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -64.05% | O: 0.93% H: 0.0% C: -4.17%
platform trial als enroll

Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -68.99% | O: 0.21% H: 0.1% C: -3.26%
treatment phase 1 therapy antibody trial phase 1b enroll

Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
Published: 2021-09-27 (Crawled : 12:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -67.87% | O: -3.57% H: 2.18% C: 0.94%
phase 3 trial

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
Published: 2021-06-23 (Crawled : 07:00) - prnewswire.com
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -54.88% | O: 0.29% H: 1.88% C: 0.25%
phase 1 collaboration trial phase 2 phase 3

Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
Published: 2021-03-29 (Crawled : 13:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -34.09% | O: -1.52% H: 0.82% C: -2.24%
funding phase 2 phase 2/3 trial enroll milestone

Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
Published: 2021-03-10 (Crawled : 00:05) - prnewswire.com
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology

| -42.24% | O: 2.38% H: 4.18% C: 2.68%
trial als enroll

Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Published: 2021-01-18 (Crawled : 15:00) - biospace.com/
BHVN | News | $44.03 0.59% -5.75% 970K

Health Technology